EP Patent

EP2259794A1 — Method for treatment of photosensitivity and phototoxicity

Assigned to Clinuvel Pharmaceuticals Ltd · Expires 2010-12-15 · 15y expired

What this patent protects

The present invention relates to the use of an alpha-MSH analogue to reduce or ameliorate photosensitivity and/or phototoxicity in a patient due to administration of a photosensitizing agent and the use of an alpha-MSH analogue for the manufacture of a therapeutic or prophylactic…

USPTO Abstract

The present invention relates to the use of an alpha-MSH analogue to reduce or ameliorate photosensitivity and/or phototoxicity in a patient due to administration of a photosensitizing agent and the use of an alpha-MSH analogue for the manufacture of a therapeutic or prophylactic preparation for treating photosensitivity and/or phototoxicity in the patient due to administration of a photosensitizing agent.

Drugs covered by this patent

Patent Metadata

Patent number
EP2259794A1
Jurisdiction
EP
Classification
—
Expires
2010-12-15
Drug substance claim
No
Drug product claim
No
Assignee
Clinuvel Pharmaceuticals Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.